Personalising breast cancer screening in Norway
Are polygenic risk scores the answer?
New incubator board member
Thomas London has joined the board of Oslo Cancer Cluster Incubator.
CellFIT workshop in Trondheim
How can manufacturing of T cell therapies be improved?
First demonstration of universal cancer vaccine
New data shows 27% improved survival in the NIPU trial.
Statsbudsjettet 2024
Her er de viktigste sakene i Statsbudsjettet 2024 for Oslo Cancer Clusters medlemmer.
SurViva joins Oslo Cancer Cluster
SurViva is a Norwegian consultancy providing quality guidance for life science companies.